Lurasidone, olanzapine, and quetiapine extended-release for bipolar depression: A systematic review and network meta-analysis of phase 3 trials in Japan.
Taro KishiReiji YoshimuraKenji SakumaMakoto OkuyaNakao IwataPublished in: Neuropsychopharmacology reports (2020)
Our results suggested although the efficacy of three SGAs was similar, there were the differences in the safety profile among the SGAs.